Key result
NO synthase inhibition with L-NAME attenuated beta2-adrenoreceptor-mediated vasodilation (ethanol ratio 0.075 vs 0.03 with D-NAME) and enhanced lipolysis and norepinephrine release.
Why the study?
Does nitric oxide synthase inhibition modulate beta-adrenergic receptor-mediated tissue perfusion and metabolism in humans?
Does nitric oxide synthase inhibition modulate beta-adrenergic receptor-mediated tissue perfusion and metabolism in humans?
Absolute Event Rate: 0.075% vs 0.03%
Nitric oxide synthase inhibition attenuates beta2-adrenoreceptor-mediated vasodilation and enhances lipolysis, suggesting NO modulates sympathetic effects in peripheral tissues.
Human microdialysis data on NO-adrenoreceptor interactions remain exploratory; leaves open clinical translation in cardiovascular disease.
Nitric oxide (NO) may be an important modulator of sympathetic tone. We used im and sc microdialysis in humans to characterize the interaction of NO synthase inhibition and adrenoreceptor stimulation on tissue perfusion, metabolism, and norepinephrine release. Microdialysis probes were perfused with L- or D-nitro-L-arginine-methyl-ester (100 micromol/L) followed by incremental doses of isoproterenol, epinephrine, or nitroprusside. Blood flow was estimated based on the ethanol dilution technique. In muscle, the increase in blood flow with isoproterenol was abolished by L-NAME. The ethanol ratio was 0.03 +/- 0.011 with D-NAME and 0.075 +/- 0.014 with L-NAME during isoproterenol treatment (1 micromol/L). The effect was less pronounced in adipose tissue. The vasodilatory effect of nitroprusside was similar with D- and L-NAME. L-NAME augmented isoproterenol- and epinephrine-induced glycerol release. Dialysate glycerol during 1 micromol/L isoproterenol was 47 +/- 6.7 micromol/L with D-NAME and 72 +/- 15 micromol/L with L-NAME. In skeletal muscle, dialysate norepinephrine during 1 micromol/L isoproterenol treatment was 0.73 +/- 0.17 and 1.3 +/- 0.15 nmol/L with D- and L-NAME, respectively. We conclude that NO synthase inhibition attenuates beta(2)-adrenoreceptor-mediated vasodilation and enhances beta-adrenoreceptor-mediated lipolysis. These effects are in part mediated through an increase in interstitial norepinephrine concentrations. The data are consistent with the idea that in humans, NO is important in modulating and ameliorating sympathetic effects in peripheral tissues.
No takes yet. Share an insight, caveat, or question.
Jordan et al. (2001) studied this question. L-NAME (NO synthase inhibition) vs. D-NAME was evaluated on Ethanol ratio in muscle during isoproterenol treatment (1 micromol/L). NO synthase inhibition with L-NAME attenuated beta2-adrenoreceptor-mediated vasodilation (ethanol ratio 0.075 vs 0.03 with D-NAME) and enhanced lipolysis and norepinephrine release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: